Rituximab in immunologic glomerular diseases
Abbreviated Journal Title
mAbs
Keywords
rituximab; glomerular diseases; transplant; rejection; FOCAL SEGMENTAL GLOMERULOSCLEROSIS; IDIOPATHIC MEMBRANOUS NEPHROPATHY; THROMBOTIC THROMBOCYTOPENIC PURPURA; ANTIBODY-ASSOCIATED VASCULITIS; DEPENDENT NEPHROTIC SYNDROME; PROLIFERATIVE LUPUS NEPHRITIS; CHRONIC; LYMPHOCYTIC-LEUKEMIA; ANCA-ASSOCIATED VASCULITIS; B-CELL DEPLETION; RENAL-TRANSPLANTATION; Medicine, Research & Experimental
Abstract
Experimental data suggest that the B-cell antigen CD20 may play a significant role in the pathogenesis of many diseases including glomerular diseases. These and other findings underpin the central concept of B-cell-depleting therapies that target CD20 antigen as treatments for lupus nephritis, idiopathic membranous nephropathy, focal segmental glomerulosclerosis, cryglobulinemic glomerulonephritis, antibody mediated renal allograft rejection and recurrent glomerulonephritis in renal allograft. Use of rituximab as a B-cell depleting therapy has been associated with clinical improvement and has emerged as a possible adjunct or alternative treatment option in this field of nephrology.
Journal Title
Mabs
Volume
4
Issue/Number
2
Publication Date
1-1-2013
Document Type
Review
Language
English
First Page
198
Last Page
207
WOS Identifier
ISSN
1942-0862
Recommended Citation
"Rituximab in immunologic glomerular diseases" (2013). Faculty Bibliography 2010s. 2601.
https://stars.library.ucf.edu/facultybib2010/2601
Accessibility Statement
This item was created or digitized prior to April 24, 2027, or is a reproduction of legacy media created before that date. It is preserved in its original, unmodified state specifically for research, reference, or historical recordkeeping. In accordance with the ADA Title II Final Rule, the University Libraries provides accessible versions of archival materials upon request. To request an accommodation for this item, please submit an accessibility request form.
Comments
Authors: contact us about adding a copy of your work at [email protected]